Toshiba at EuroCIS: Empowering Retailers to “Create Your Tomorrow”
13.2.2025 09:00:00 CET | Business Wire | Press release
Attendees will experience solutions for secure, seamless, and personalized shopping
At EuroCIS 2025, Toshiba Global Commerce Solutions showcases how it empowers retailers with its innovative solutions portfolio for smart stores, customer personalization, and security (booth in hall 9 #B42). The international trade fair will take place on February 18-20 in Düsseldorf, Germany.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250213535650/en/
The new TCx 820 all-in-one POS system is suitable for all types of store environments as it is available in various formats and screen sizes. (Photo: Business Wire)
“In a world brimming with possibilities, every retailer can shape their own future and deliver exceptional customer experiences and growth with the help of an experienced partner,” says Robin Lyon, Executive Director of Channels & Marketing, Toshiba Global Commerce Solutions. “To empower retailers to create their own tomorrow, Toshiba delivers complete solutions comprising of its modular MxP® hardware, software and services harnessing the power of AI, computer vision, and other transformative technologies. Advanced self-service solutions and new POS technologies are designed to meet the unique needs of retailers, no matter their size or segment.”
Innovative Solutions shown on the Toshiba booth
- Loss prevention and customer experience at self-checkout: The new Modular eXpansion Platform (MxP®) provides self-checkout solutions in a sleek design tailored for all retail segments. Various form factors feature capabilities for loss prevention and produce recognition using AI, computer vision and IoT sensors to recognize shrinkage and speed up transactions. Toshiba’s TCx® EDGEcam+ cameras monitor customer behaviors without in-store servers, enhancing security throughout the checkout area. For fast scan-free self-checkout, the MxP® VisionKiosk uses computer vision and AI to automatically identify items for a seamless shopping experience.
- Flexible POS-systems and versatile Touch Displays: The new TCx® 820 all-in-one POS-system and TCx® Touch Displays are available in multiple formats with a sleek design ready for all retail segments. They are configurable in five formats enabling seamless integration into any retail environment or use case. Screen sizes range from 10” to 24” with both landscape and portrait orientations available.
- Personalized shopping experiences: Catch Retail is an AI retail media platform for physical spaces, monetizing first-party data for retailers and brands, enabling them to reach new, targeted audiences in stores. Catch will demonstrate how they are revolutionizing in-store customer engagement, brand loyalty and revenue growth by enabling personalized media through various shopping touchpoints.
- AI-powered refrigeration management: Axiom Cloud will demonstrate how retailers can reduce energy consumption and save on maintenance costs in their cold chain operations using AI.
- Toshiba Commerce Marketplace: Aimed at meeting the ever-evolving needs of retail, the Toshiba Commerce Marketplace enables retailers to connect to an extensive network of industry-leading technology partners and solutions to stay competitive in an increasingly digital world, to enhancebusiness operations, and improve the shopping experience. Today, the Commerce Marketplace includes partners such as Adyen, Zebra, Datalogic, Ingenico, Ecrebo, Qualcomm, Honeywell, and Aptos, amongst others.
Toshiba will speak on the Blue and Red Stages
Toshiba experts will also share their knowledge and expertise on the EuroCIS stages:
February 18 at 11:40 - 12:00 on the Blue Stage (hall 10 G65)
The Business Benefits of Switching to a Secure Retail Cloud
Johnny Flynn, Retail Cloud Architect, Toshiba Global Commerce Solutions
February 19 at 14:00 - 14:20 on the Red Stage (hall 10 G01)
From Simple Break-Fix Maintenance to Sustainable Business Availability Management
Catherine Bataille, Director Professional Services, Toshiba Global Commerce Solutions
Dries de Beul, Technical Design & Solution Architect, Toshiba Global Commerce Solutions
To arrange to meet with Toshiba at EuroCIS, follow this link: Book a Meeting with Toshiba
About Toshiba Global Commerce Solutions:
Toshiba Global Commerce Solutions empowers retail to thrive and prosper through a dynamic ecosystem of smarter, more agile solutions and services that enable retailers to resiliently evolve with generations of consumers and adapt to market conditions. Supported by a global organization of devoted employees and partners, retailers gain more visibility and control over operations while enjoying the flexibility to build, scale, and transform retail experiences that anticipate and fulfill consumers’ ever-changing needs.
Visit commerce.toshiba.com and engage with us on:
LinkedIn - YouTube - Facebook - Instagram: @toshibacommerce
X/Twitter: @ToshibaCommerce
Toshiba Global Commerce Solutions is a wholly owned subsidiary of Toshiba Tec Corporation, which is traded on the Tokyo Stock Exchange.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250213535650/en/

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release
Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere
The Premier Jumping League (PJL) Launches with a Record-Breaking $300 Million Guaranteed Prize Pot, Defining a New Era for Showjumping30.3.2026 11:00:00 CEST | Press release
The PJL empowers riders to compete as full-time professional athletes while working towards a sustainable economic model for the sport. Backed by McCourt Global and shaped by a leadership team with decades of experience in equestrian competition, sport, and entertainment, the PJL sets a new, sustainable, and globally relevant standard for elite jumping. Sixteen teams will compete across fourteen iconic international venues throughout Europe, North America, and the Middle East when the inaugural season opens in March 2027. The Premier Jumping League (PJL) launches with a record-breaking $300 million guaranteed prize pot, defining a new era for showjumping. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330990938/en/ Photography credits: Daniel Benson for The Premier Jumping League/ Wieden+Kennedy London Backed by McCourt Global and its Executive Chairman, Frank McCourt, the PJL is a groundbreaking global competition that e
Dompé Announces First Patient Enrolled in New Study of Intranasal NGF in Cerebral Palsy30.3.2026 11:00:00 CEST | Press release
Cerebral Palsy (CP) refers to a group of permanent disorders in the development of movement and posture, which causes activity limitations, and is attributed to non-progressive disturbances that occurred in the developing fetal or infant brain.1 Nerve growth factor (NGF) is a naturally-occurring protein that supports damaged nerve cells and improves nervous system signaling, Dompé is investigating whether intranasal NGF has the potential to improve movement and neurodevelopment and address underlying brain damage in people with CP. Dompé’s intranasal NGF platform builds on the Nobel Prize-winning discovery of neurobiologist Professor Rita Levi-Montalcini and biochemist Dr. Stanley Cohen. Dompé, a leading biopharmaceutical company with operations in Italy and in the U.S., announced that the first patient has been enrolled at the Agostino Gemelli IRCCS University Hospital in Rome, Italy, in a Phase 2 investigational study of an intranasal form of Nerve Growth Factor (NGF) (Cenegermin-bkb
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom